Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man
- 1 January 1992
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 17 (1) , 21-27
- https://doi.org/10.1007/bf03189983
Abstract
The metabolic fate of isoxicam, a long half-life non-steroidal anti-inflammatory agent, in human subjects was investigated using isoxicam labelled with14C in the N-methyl position. Three healthy male subjects were each administered a single oral 200 mg dose (90.7 μCi) with plasma and urine collected. Total plasma radioactivity peaked between 8 and 24 h postdose with mean14C plasma radioactivity half-life of 36.1 h. Low levels of plasma radioactivity precluded plasma metabolic profiling. In urine, 37% of the administered radioactivity was recovered through 168 h. Metabolic profiling of urine confirmed the major oxidative excretion product as the hydroxymethlyisoxazole metabolite. Identified and confirmed as minor urinary metabolites were radiolabelled open-ring sulfonamide and N-methylsaccharin. Non-labelled saccharin formed by oxidative loss of the14C N-methyl group from N-methylsaccharin, was also observed. The role of this ‘saccharin pathway’ in the overall human disposition of isoxicam remains to be elucidated.Keywords
This publication has 14 references indexed in Scilit:
- Oxicams: Metabolic Disposition in Man and AnimalsDrug Metabolism Reviews, 1989
- In vitrometabolism of isoxicam by horseradish peroxidaseXenobiotica, 1989
- TenoxicamDrugs, 1987
- Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.British Journal of Clinical Pharmacology, 1986
- Metabolism of tenoxicam in ratsXenobiotica, 1984
- A double-blind multicenter study comparing isoxicam and indomethacin in the treatment of degenerative joint diseaseSeminars in Arthritis and Rheumatism, 1982
- Comparative studies of isoxicam in rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1982
- Aspirin-and placebo-controlled study of isoxicam in the treatment of rheumatoid arthritisSeminars in Arthritis and Rheumatism, 1982
- Placebo-controlled multicenter studies in the treatment of rheumatoid arthritis and degenerative joint diseaseSeminars in Arthritis and Rheumatism, 1982
- The anti-inflammatory properties of isoxicam (4-hydroxy-2-methyl-N-[5-Methyl-3-isoxolyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide])Inflammation Research, 1975